Korro Bio, Inc. (KRRO): restructuring charge — Korro Q1 net loss $23.4M; workforce reduction of 20%, cash runway into 2027

Korro Bio, Inc.

Net loss $23.4M vs $19.6M YoY; collaboration revenue $2.6M from Novo Nordisk.
Cash, cash equivalents and marketable securities $139.0M, expected to fund operations into 2027.
Workforce reduction of approximately 20%; one-time restructuring charges ~$1.2M in Q2 2025.
Phase 1/2a REWRITE trial interim readout for KRRO-110 expected H2 2025; trial completion in 2026.
Expect to nominate second development candidate in 2025; Novo Nordisk cardiometabolic collaboration ongoing.

item 2.02 item 2.05 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Korro Bio, Inc. announced a restructuring with charges of approximately $1.2 million (approximately 20%).

Type: restructuring
Charge: approximately $1.2 million
Headcount: approximately 20%

Exact text from the filing

Korro estimates that it will incur one-time restructuring charges of approximately $1.2 million including employee severance, benefits and related termination costs, the majority of which Korro expects to recognize during the three months ended June 30, 2025.

View on SEC.gov

Browse all restructurings & charges →

Korro Bio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-065786

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.